Pocket Program - CROI

Poster Listings
Session 53 CROI 2013
c Monday, 2:30-4 pm; Hall B2
Session 53–Poster Abstracts
HIV Persistence, Reservoirs, and Viremic Control
170aLB Impact of Interleukin-7 and Raltegravir + Maraviroc
Intensification on Total HIV DNA Reservoir: Results from
ERAMUNE 01
Christine Katlama* 1 , S Lambert 2 , L Assoumou 3 , L Papagno 4 ,
F Lecardonnel 4 , G Tambussi 5 , B Clotet 6 , M Youle 7 , D Costagliola 3 ,
B Autran 8 , and ERAMUNE-01 Study Group
1 Hosp Pitie-Salpetriere, Paris, France;; 2 Lab of Virology, Univ Pierre
et Marie Curie Paris 6, INSERM U943, France;; 3 Univ Pierre et Marie
Curie Paris 6, INSERM U943, France;; 4 ORVACS with the support of
the Bettencourt-Schueller Fndn;; 5 San Raffaele Hosp, Milan, Italy;; 6 Hosp
Univ Germans Trias i Pujol, Fndn irsiCaixa, Badalona, Spain;; 7 Royal
Free Hosp NHS Trust, London, UK;; and 8 Lab of Cellular and Tissular
Immunology, Univ Pierre et Marie Curie Paris 6, INSERM U945, France
175LB Natural Killer Cells Can Target and Eliminate Latently
HIV-1 + Primary T Cells following Proviral Reactivation
Mary Ann Checkley Luttge*, C Dobrowolski, M Shukla, B Luttge,
H Mao, and J Karn
Sch of Med, Case Western Reserve Univ, Cleveland, OH, US
+ 176LB
T Cells Is
Associated with Lack of Progression in Viremic Individuals
Nichole Klatt* 1,2 , S Bosinger3 , A Specht4 , M Lederman5 , D Camerini6 ,
M Paiardini3 , J Brenchley2 , F Kirchhoff4 , P Hunt7 , and G Silvestri3 1 2 Washington Natl Primate Res Ctr, Univ of Washington, Seattle, US;; Lab
of Molecular Microbiology, NIAID, NIH, Bethesda, MD, US;; 3Yerkes Primate Res Ctr, Emory Vaccine Ctr, Emory University, Atlanta, GA, US;;
4 5 Inst of Molecular Virology, Ulm Univ Med Ctr, Germany;; Case Western
Reserve Univ/Univ Hosp Case Med Ctr, Cleveland, OH, US;; 6Inst for
Immunology, Univ of California, Irvine, US;; and 7UCSF Positive Hlth
Prgm, San Francisco, CA, US
177LB
Response in HIV-1 Superinfection
Antoine Chaillon* 1,2 , G Wagner 1 , J Wertheim 1 , L Hepler 1 , S Kosakovsky
Pond 1 , G Caballero 1 , M Pacold 3 , T Wrin 4 , D Richman 1,5 , and D Smith 1,5
1 Univ of California, San Diego, La Jolla, US;; 2 INSERM UMR U966,
Tours, France;; 3 Life Technologies, Foster City, CA, US;; 4 Monogram
BioSci, Inc, San Francisco, CA, US;; and 5 VA San Diego Hlthcare System,
CA, US
24 20th Conference on Retroviruses and Opportunistic Infections
c Wednesday, 2:30-4 pm; Hall B2
Session 54–Poster Abstracts
ART, Complications, and TB
178LB
Results
Scott Letendre* 1 , A Mills 2 , K Tashima 3 , D Thomas 4 , S Min 4 , S Chen 4 ,
I Song 4 , S Piscitelli 4 , and extended ING116070 Study Team
1 UCSD Antiviral Res Ctr, San Diego, CA, US;; 2 Anthony Mills MD, Inc,
Los Angeles, CA, US;; 3 The Miriam Hosp, Providence, RI, US;;
and 4 GlaxoSmithKline, Research Triangle Park, NC, US
170bLB Early Viral Dynamics after Cord Blood Stem Cell
+
Patients
M Nijhuis1 , M Kwon2 , J Kuball1 , P Ellerbroek1 , J Berenguer2 , A Stam1 ,
J Symons1 , D Richman3 , JL Diez-Martin2 , Annemarie Wensing* 1 ,
and European HIV Cure and Transplant Consortium
1 2 Univ Med Ctr Utrecht, The Netherlands;; Gregorio Maranon G U Hosp,
Madrid, Spain;; and 3Univ of California, San Diego, US
171LB
competent HIV Reservoirs in Perinatally Infected Youth
Treated from Infancy: Towards Cure
Katherine Luzuriaga* 1 , YH Chen2 , C Ziemniak2 , G Siberry3 , M Strain4 ,
D Richman4 , T-W Chun5 , C Cunningham6 , and D Persaud2 1 2 Univ of Massachusetts Med Sch, Worcester, US;; Johns Hopkins Univ
Sch of Med, Baltimore, MD, US;; 3Maternal and Pediatric Infectious
Disease Branch, NICHD, NIH, Bethesda, MD, US;; 4Univ of California
San Diego, La Jolla and VA San Diego Hlthcare System, US;; 5NIAID, NIH, Bethesda, MD, US;; and 6Duke Univ Sch of Med, Durham, NC, US
172LB HIV-1 DNA Decay Patterns in Blood during More than a
Guillaume Besson* 1 , C Lalama2 , R Bosch2 , R Gandhi3 , M Bedison1 ,
E Aga2 , S Riddler1 , D McMahon1 , F Hong1 , and J Mellors1 1Univ of Pittsburgh Sch of Med, Division of Infectious Diseases, PA, US;;
2Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, Boston, MA,
US;; and 3Massachusetts Gen Hosp and Ragon Inst, Harvard Med Sch,
Boston, US
173LB Multifocal Detection of HIV-1 RNA in Lymphatic Tissues
during Early Viral Recrudescence after Treatment Interruption
Meghan Rothenberger* 1 , M Stevenson2 , G Beilman1 , J Chipman1 ,
A Khoruts1 , C Fletcher3 , C Reilly1 , S Wietgrefe1 , A Haase1 , and T Schacker1 1 2 3 Univ of Minesota, Minneapolis, US;; Univ of Miami, FL, US;; and Univ
of Nebraska, Omaha, US
174LB A Rapid Virion Recovery Assay Reveals a Larger Population
+
T Cells than
Previously Recognized
Michele Sobolewski* 1 , A Cillo1 , C Lalama2 , R Bosch2 , and J Mellors1 179LB
Anton Pozniak*
1 2 Univ of Pittsburgh, PA, US and Harvard Univ, Boston, MA, US
1 , H Mingrone2 , A Shuldyakov3 , C Brites4 , J Andrade5 ,
D Hagins6 , C Beltran Buendia7 , D Dorey8 , S Griffith9 , and S Min9 1 2 Chelsea and Westminster Hosp, London, UK;; Ciudad Autonoma de
Buenos Aires, Argentina;; 3Saratov Regional Ctr of Prophylactic AIDS,
Russian Federation;; 4Hosp Univ Professor Edgar Santos, Salvador,
Brazil;; 5Hosp Civil de Guadalajare Fray Antonio Alcalde, Mexico;;
6 7 Chatham CARE Ctr, Savannah, GA, US;; Hosp Barros Luco Trudeau,
Santiago, Chile;; 8GlaxoSmithKline, Mississauga, Canada;;
and 9GlaxoSmithKline, Research Triangle Park, NC, US
180LB
RTI or Raltegravir in HIV + st
-
Mark Boyd and SECOND-LINE Study Team
The Kirby Inst, Univ of New South Wales, Sydney, Australia
181LB Increasing Retention of Patients Starting ART: Karonga
Rein Houben* 1 , T Mzembe2 , T van Boeckel3 , L Munthali2 , P Mzumara4 ,
A Jahn5 , F Chimbwandira5 , J Glynn1 , and A Crampin1,2 1 2 London Sch of Hygiene and Tropical Med, UK;; Karonga Prevention
Study, Chilumba, Malawi;; 3Univ Libre de Bruxelles, Belgium;; 4Karonga District Hosp, Malawi;; and 5Ministry of Hlth, Lilongwe, Malawi
182LB Efficacy and Safety of Maraviroc to Prevent Immune
Reconstitution Inflammatory Syndrome in High-risk
Juan Sierra-Madero* 1 , A Tierney2 , M Rassool3 , L Azzoni4 , I Sereti5 ,
J Andrade6 , L Mosqueda-Gomez7 , A Pineirua1 , I Sanne3 , M Lederman8 ,
and CADIRIS Study Team
1Inst Nacional de Ciencias Med y Nutricion SZ, Mexico City, Mexico;;
2 3 Univ of Pennsylvania, Philadelphia, US;; Clin HIV Res Unit Faculty
of Hlth Sci, Univ of the Witwatersrand;; 4The Wistar Inst, Philadelphia,
PA, US;; 5NIAID, NIH, Bethesda, MD, US;; 6Hosp Civil de Guadalajara,
Mexico;; 7Capasits, Leon, Mexico;; and 8Case Western Reserve Univ,
Cleveland, OH, US
183LB No Difference in Risk of Preterm Birth among Pregnant
Ugandan Women Randomized to Lopinavir/Ritonavir vs
Deborah Cohan* 1 , P Natureeba2 , A Plenty1 , F Luwedde2 , J Mwesigwa2 ,
V Ades3 , B Nzarubara2 , T Clark1 , B Osterbauer1 , and E Charlebois1 1 2 Univ of California, San Francisco, US;; Infectious Disease Res
Collaboration, Kampala, Uganda;; and 3New York Univ, NY, US
st 184LB
-Line ART Do Not Persist
+
African Children:
The 5-Year ARROW Trial
Patricia Nahirya-Ntege* 1 , A Cook2 , V Musiime3 , A Kekitiinwa4 , K
Nathoo5 , P Munderi1 , P Mugyenyi3 , S Bakeera-Kitaka4 , S Walker2 , and D Gibb2 1 2 MRC/UVRI Uganda Res Unit on AIDS, Entebbe;; MRC Clinical Trials
Unit, London, UK;; 3Joint Clinical Res Ctr, Kampala, Uganda;; 4Baylor- Uganda/Paediatric Infectious Diseases Clin, Mulago, Kampala;; and
5Univ of Zimbabwe, Harare
185LB Non-Calcified Coronary Plaque and Macrophage Activation
Markers Are Increased in HIV + Women
Kathleen Fitch* 1 , S Abbara 1 , T Burdo 2 , K Williams 2 , P Eneh 1 , J Lo 1 ,
and S Grinspoon 1
1 Massachusetts Gen Hosp, Boston, US and 2 Boston Coll, Chestnut Hill, MA, US
186LB Effect of Statins on Immune Activation and Inflammation in
HIV +
Trial
Grace McComsey* 1,2,3 , Y Jiang 1 , S Debanne 1 , B Clagett 1 , J Robinson 1 ,
D Labbato 1,2,3 , N Storer 1,2,3 , M Lederman 1,2 , and N Funderburg 1
1 Case Western Reserve Univ, Cleveland, OH, US;; 2 Univ Hosp Case Med
Ctr, Cleveland, OH, US;; and 3
Cleveland, OH, US
187LB
Craig Sponseller* 1 , R Morgan 2 , S Campbell 2 , J Aberg 3 , and M Thompson 4
1 Kowa Pharmaceuticals America, Inc, Montgomery, AL;; 2 Kowa Res Inst,
Inc, Morrisville, NC, US;; 3 New York Univ Sch of Med, NY, US;; and 4 AIDS
Res Consortium of Atlanta, GA, US